Patents Examined by Lawrence E. Crane
  • Patent number: 10570385
    Abstract: A non-enzymatic method is provided for binding a first nucleic acid chain to a second nucleic acid chain without introducing a sulfur atom into the combined nucleic acid chain, the method comprising reacting a first nucleic acid chain having a phosphorothioate group at the 3? or 5? terminus with a second nucleic acid chain having a hydroxyl group or an amino group at the 3? or 5? terminus in the presence of an electrophile that has a leaving group and is configured to leave the leaving group and bind to a sulfur atom of the phosphorothioate group of the first nucleic acid chain at the site to which the leaving group had been bound, and remove the sulfur atom from the phosphorothioate group of the first nucleic acid chain and a hydrogen atom from the hydroxyl group or from the amino group of the second nucleic acid chain via a nucleophilic substitution with an oxygen atom of the hydroxyl group or a nitrogen atom of the amino group of the second nucleic acid chain, and thereby form a bond between a phosphorus a
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: February 25, 2020
    Assignee: Japan Science and Technology Agency
    Inventors: Hiroshi Abe, Hideto Maruyama
  • Patent number: 10555967
    Abstract: Broth compositions prepared from poultry materials are disclosed. Selected poultry raw materials are processed to obtain a broth having high protein content and high chondroitin sulfate. Certain specific amino acids are present at higher concentration as compared to home-made broth and other commercial products. The disclosed broth compositions are effective in preventing and/or treating joint diseases and may also provide other nutritional and health benefits.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 11, 2020
    Inventors: Roger L. Dake, Stephanie Lynch, Paul L. Durham, Ryan J. Cady, Jordan L. Hawkins
  • Patent number: 10519185
    Abstract: Disclosed herein are methods of preparing a nucleoside analog, Compound (I): or a pharmaceutically acceptable salt thereof, which is useful in treating diseases and/or conditions such as viral infections, and intermediates thereof.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: December 31, 2019
    Inventors: Vladimir Serebryany, Jyanwei Liu, Leonid Beigelman
  • Patent number: 10513536
    Abstract: A method of obtaining a polyalkoxylated nucleic acid, which can be used to make a modified drug, from a liquid mixture of polyalkoxylated and non-polyalkoxylated nucleic acids is described. The method involves use of a solvent or a mixture of solvents that allow the polyalkoxylated nucleic acids to precipitate out of the solution.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: December 24, 2019
    Assignee: NOXXON Pharma AG
    Inventor: Lucas Bethge
  • Patent number: 10494398
    Abstract: This invention relates to antisense oligonucleotides comprising at least one N3??P5? phosphorodiamidate linkage (NPN) in the backbone, useful for modulating gene expression involved in the pathogenesis of a disease. Compounds useful as building blocks of said antisense oligonucleotides and methods of preparing building block compounds including NPN linkages are provided.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: December 3, 2019
    Assignee: Geron Corporation
    Inventors: Krisztina Pongracz, Mahesh Ramaseshan
  • Patent number: 10463683
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: November 5, 2019
    Assignee: Celgene Corporation
    Inventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • Patent number: 10463685
    Abstract: Methods for treating a telomerase-expressing cell characterized by an over-activation of telomerase in a subject in need thereof comprising administering a pharmaceutical composition comprising a first amount of a 6-mercaptopurine analog, and a second amount of a telomerase inhibitor, wherein the first amount and the second amount together comprises an amount effective to reduce stability of telomere length and to induce cell death in the telomerase-expressing cell are provided. The methods can be used to treat patients with lung cancer, colon cancer, or cervical cancer.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: November 5, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Jerry W. Shay, Sergei M. Gryaznov
  • Patent number: 10457931
    Abstract: Disclosed is a process for purifying nucleic acids, especially plasmid DNA, from a nucleic acid-containing, biologic sample, consisting of (a) preparation of a fluid sample containing nucleic acid and endotoxin each in dissolved form; (b) precipitation at least of nucleic acid and endotoxin from the fluid sample; (c) washing of the components of the fluid sample precipitated out in step b) in order to at least partially remove the endotoxin with at least one washing solution, which contains at least one amine compound with at least two carbon atoms and with a molar mass of ?500 g/mol and; at least one organic solvent different from the aforementioned amine compound and has a pH-value (20° C.) in the range from pH 3.0 to pH 8.5, and; (d) dissolution of the remaining nucleic acid from the washed, precipitated constituents from step c) using a dissolving buffer and collection of the dissolved nucleic acids in a separate receptacle. The process is suitable for the effective and economical removal of endotoxins.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: October 29, 2019
    Assignee: AXAGARIUS GMBH & CO. KG
    Inventors: Stefan Heymans, Thorsten Rosenbaum
  • Patent number: 10434086
    Abstract: Provided herein are methods and compositions that relate to, inter alia, CBL0137, a carbazole compound 1,1?-[9-[2-[(1-methylethyl)amino]ethyl]-9H-carbazole-3,6-diyl]bis-ethanone, useful for the treatment of various cancers, optionally in combination with various agents.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: October 8, 2019
    Assignee: Incuron, Inc.
    Inventor: Catherine Burkhart
  • Patent number: 10428019
    Abstract: The disclosed and claimed compounds are chiral auxiliaries useful for efficiently producing a phosphorus atom-modified nucleic acid derivative with high stereoregularity. The disclosed and claimed compounds include those represented by the following formula (I) or formula (XI) for introducing the chiral auxiliaries.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: October 1, 2019
    Inventors: Takeshi Wada, Mamoru Shimizu
  • Patent number: 10420757
    Abstract: The current disclosure relates to methods for treating pancreatic cancer or chronic pancreatitis in a subject comprising administering an antagonist of a dopamine receptor to the subject wherein the dopamine receptor is, in some specific cases dopamine receptor D2 (DRD2). The antagonist in some specific cases is an RNAi construct, an antibody, or a small molecule and in more specific cases pimozide or L-741,626. The disclosure also relates to diagnostic methods comprising the detection of the expression of DRD2 in pancreatic tissue and kits for doing the same.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: September 24, 2019
    Assignees: Deutsches Krebsforschungszentrum Stiftung des Öffentlichenrechts, The Royal Institution for the Advancement of Learning/McGill University
    Inventors: Pouria Jandaghi, Jörg Hoheisel, Yasser Riazalhosseini
  • Patent number: 10414790
    Abstract: The present invention provides nucleosides an exocyclic amine-protected nucleoside of the formula: A-B where A is a 5?-protected ribose, 5?-protected-2-deoxyribose, 5?-protected-3?-phosphoramidite ribose, or 5?-protected-3?-phosphoramidite-2-deoxyribose moiety; and B is a nucleobase having an exocyclic amine group that is protected with di-tert-butylisobutylsilyl (“BIBS”) protecting group. Use of BIBS protecting group provides an exocyclic amine-protected nucleoside that is stable to a wide variety of reaction conditions associated with oligonucleotide synthesis. The present invention also provides, oligonucleotides comprising the same, and methods for producing the same.
    Type: Grant
    Filed: August 3, 2013
    Date of Patent: September 17, 2019
    Assignee: The Regents of the University of Colorado
    Inventors: Marvin H. Caruthers, Subhadeep Roy
  • Patent number: 10385090
    Abstract: Disclosed is a nucleoside derivative of formulae (I-1) or a salt thereof: in which R1, R2, R3, R5, A1 to A3, B, X, Y, and k are described herein. Also provided are a 5?-phosphate ester and a 3?-phosphoramidite derivative of the nucleoside derivative and substrate solutions thereof. A polynucleotide is produced using the 5?-phosphate ester or 3?-phosphoramidite derivative of the nucleoside derivative. A library of the produced polynucleotide is used in a method of selecting a nucleic acid aptamer. Further provided is a vesicular endothelial growth factor binding agent of formula (i).
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: August 20, 2019
    Inventor: Masayasu Kuwahara
  • Patent number: 10385088
    Abstract: The present disclosure provides alternative sugar moieties and polynucleotides comprising such sugar moieties, and methods of use thereof.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: August 20, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Andrew W. Fraley, Atanu Roy, Matthew Stanton
  • Patent number: 10376529
    Abstract: The present invention is related to a product comprising a pentacyclic triterpene of formula (I) and a hydroxytyrosol or derivatives thereof of formula (II), pharmaceutical compositions thereof and their uses as antioxidants, anti-inflammatories and neuron protectors.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: August 13, 2019
    Assignee: NATAC BIOTECH, S.L.
    Inventors: José Carlos Quintela Fernández, Esther De La Fuente García, Marco Pugliese, Pilar Mancera Aroca, Javier Bustos Santafé, Juan Francisco Espinosa Parrilla, Noemí Virgili Treserres, Blanca Wappenhans Battestini
  • Patent number: 10378011
    Abstract: An oligonucleotide having improved affinity for AGO2 is disclosed. The oligonucleotide has a nucleotide residue or a nucleoside residue represented by formula (I) wherein X1 is an oxygen atom or the like, R1 is formula (IIA), wherein R5A is halogen or the like, and R6A is a hydrogen atom or the like, or formula (IVA) wherein Y3A is a nitrogen atom or the like, and Y4A is CH or the like, or the like, R2 is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R3 is a hydrogen atom or the like at the 5? end thereof, and the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3. A method for improving the knockdown activity of an oligonucleotide wherein the oligonucleotide has a knockdown activity against an mRNA encoding a protein involved in a disease.
    Type: Grant
    Filed: September 2, 2013
    Date of Patent: August 13, 2019
    Inventors: Fumikazu Shinohara, Asana Makino, Junichiro Yamamoto, Taiji Oashi, Michihiko Suzuki, Jun-ichi Saito, Takahiro Nakajima, Tomoyuki Nishikawa, Masayoshi Nakoji, Yuichi Takahashi
  • Patent number: 10377789
    Abstract: A compound represented by formula I or II below or a salt thereof: wherein B1 represents a purin-9-yl group or a 2-oxo-1,2-dihydropyrimidin-1-yl group that has any one or more substituents selected from the group consisting of a hydroxyl group, a hydroxyl group protected by a protecting group in nucleic acid synthesis, a C1 to C6 linear alkyl group, a C1 to C6 linear alkoxy group, a mercapto group, a mercapto group protected by a protecting group in nucleic acid synthesis, a C1 to C6 linear alkylthio group, an amino group, a C1 to C6 linear alkylamino group, an amino group protected by a protecting group in nucleic acid synthesis, and a halogen atom.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: August 13, 2019
    Assignee: Osaka University
    Inventors: Satoshi Obika, Yutaro Kotobuki, Reiko Waki
  • Patent number: 10350231
    Abstract: 2-Chloro-2?-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of neuromyelitis optica, hereinafter referred to as NMO e.g. in patients known to have NMO-IgG seropositivity or in patients optic neuritis, myelitis and at least two of MRI evidence of contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis or NMO-IgG seropositivity.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: July 16, 2019
    Assignee: Chord Therapeutics S.a.r.l.
    Inventors: Arthur Henry Roach, Konrad Rejdak
  • Patent number: 10351586
    Abstract: The present disclosure provides cytidine derivative dimers, salts and compositions of the cytidine derivative dimers, and methods of making and using the cytidine derivative dimers. The disclosed compounds are useful for treating a neoplasm in mammalian subjects. The cytidine derivative dimer has the following general formula (I). where R1 is C1-C10 alkyl, C1-C10 substituted alkyl, —(CH2)n-Ph, or substituted —(CH2)n-Ph; R2 is C1-C10alkyl, C1-C10 substituted alkyl, —(CH2)n-Ph, or substituted —(CH2)n-Ph; R3 is hydrogen, alkoxycarbonyl or substituted alkoxycarbonyl; R4 is hydrogen, alkoxycarbonyl or substituted alkoxycarbonyl; and R5 is —(CH2)n—, substituted —(CH2)n—, or —(CH2)n1—O—(CH2)n2-Ph-, where n, n1, and n2 are an integer from 0 to 3. The disclosed cytidine derivative dimers/salts provide high anti-tumor activity with low toxicity and are useful for treating cancers.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: July 16, 2019
    Inventors: Daria Yang, Haidong Wang, Hui-Juan Wang
  • Patent number: 10342817
    Abstract: The present invention relates to pharmaceutical compositions and combination therapies for treating patients having a neoplasm or a proliferative disorder, the combination comprises ribavirin, GDC-0449 and a chemotherapeutic agent, wherein said combination therapy overcomes resistance developed in patients during anti-neoplastic treatment. The present invention also provides a combination therapy for treating patients having leukemia.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: July 9, 2019
    Assignee: Universite de Montreal
    Inventors: Katherine Borden, Hiba Zahreddine, Biljana Culjkovic Kraljacic